SCHEMBL26314793

SCHEMBL26314793

Cc1ncccc1-c1c(Br)ccc2nc(O)ncc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 5/20 0.36
▸ MKNK1 Q9BUB5 1/20 0.36
▸ MKNK2 Q9HBH9 1/20 0.36
▸ PDPK1 O15530 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.33
▸ PDE2A O00408 4/20 0.32
▸ PDE10A Q9Y233 4/20 0.32
▸ ELANE P08246 1/20 0.32
▸ TDO2 P48775 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ HSP90AA1 P07900 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ PPARG P37231 1/20 0.30
▸ COMT P21964 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24109001 0.71 RXFP1 (0.44) DHODHHTTKMT2ASMN1; SMN2PPARG
SCHEMBL1571411 0.70 ESR1 (0.35) —
SCHEMBL28317952 0.64 CYP2A6 (0.39) PDE2AMEN1KMT2ASMN1; SMN2
SCHEMBL31469002 0.63 MKNK1 (0.52) MKNK1MKNK2PDE2APDE10AELANE
SCHEMBL3421959 0.63 MKNK1 (0.52) MKNK1MKNK2PDE2APDE10AELANE
SCHEMBL3952706 0.61 ALDH1A1 (0.48) KDM4EMEN1TP53HSP90AA1HTT
SCHEMBL16225639 0.60 — —
SCHEMBL4446669 0.60 MKNK1 (0.46) MKNK1MKNK2TDO2KDM4EMEN1
SCHEMBL113672 0.59 — —
SCHEMBL29653537 0.59 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-08-17 — — US disclosed
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2A, MAT2B, MAT1A DHODH 964/4885MKNK1 771/4885MKNK2 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback